Pfizer, daily weight loss after liver injury Danugliprron

Pfizer He said he would complete the development of his experimental on Monday Daily weight loss pill After a patient, he had a potentially a liver injury by a convicted drug.

The patient did not experience symptoms or side effects associated with the liver, a Pfizer spokesman said in a statement. They added that the patient’s liver enzymes “quickly recovered”, after taking a pill-1 drug from the mouth called Danuglipron, “he recovered rapidly.” Statement shows that the patient’s liver enzymes often rise damage to cells In the body and there is an issue associated with a number of other obesity medications.

During the period of preparation, the court took place in the trial quickly increasing the dose of the pill. Pfizer’s decision to stop the development of the drug “To date, so far to date to date, including the recommendation of information, including the recent entrances of the information,” the sum of information, including the sum of information, “.

“When we stop developing Danugliprron, we remain committed to evaluating and developing promising programs to bring new medicines to the patients,” said Dr. Chris Boshoff, Pfizer’s senior scientist and released. He added that the company still develops other weight loss medications.

The announcement is a number of a number of a number of a number of a number of a number with a series of a number with a company’s offer to gain a slice market for GLP-1s, which imitates certain intestinal hormones to lower the appetite and adjust the blood sugar. Pfizer is one of the few druggists in a row to bring a pound of pounds a more convenient weight to a place of weekly injections, but for years behind rivals such as Eli lilli and Novo Nordisk.

Some Wall Street analysts expect the GLP-1 industry to be more than $ 150 billion in the early 2030s. Oral GLP-1S, if this common, injection considers the rest, Some analytical estimates.

This is Danugliprron, Pfizer, is not particularly retreat. Company stopped In December 2023 of the patients, twice the pills, the medication on the shared stage was difficult to endure drugs.

But Pfizer once Danugliprron once turned out to be confident in the form of Danugliprron Start conducting research In the second half of the year to assess the dose of the pill.

Despite the decision to break the drug, Pfizer said that these studies meet with the main goals and the potential of the pill and the potential to convey the “competition efficiency and endurance”.

The company also noted that speed is High liver enzymes In people who receive Danugliprron, more than 1,400 patients receiving Pfizer’s pill correspond to approved GLP-1 medications based on the security database.

Pfizer, daily obesity pill in June 2023, after patients receiving this medicine, the average phased patients reached the higher liver enzment. Investors have been a pessimistic about the company’s potential since today.

Still there is pfizer Other experimental In the early stages of development, obesity drugs in the pipeline are now working differently. This includes a medicinal medication that blocks another intestinal hormone, once a daily oral GLP-1 once a day once a time last year.

Pfizer believes that a drug targeting can be more effective and more effective for patients to endure patients, since the company since today, the company has reported to investors in October since the company. Added that “there is so much application for GLP-1S.”

Pfizer’s Danugliprron promotes weight loss by targeting GLP-1, which is also a novo nordiskin weight loss injection wegovy and diabetes treatment ozempical work. Eli Lilly’s weight loss Injection Zepbound and Diabetes Shot Mounjaro Target GLP-1, also activate another intestinal hormone called GIP.

So far, the only oral GLP-1 approved by the Department of Food and Drug Administration is Rybelsus, who is treated by $ 2.38 billion in diabetes Sales In 2024.

The announcement of the Pfizer Monday, the company also comes as it stood up and Restores stock price After the fasteneration of the covig work. Pfizer bets on the pipeline of cancer drugs to ensure long-term growth, but stressed that the main focus of fat.